Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library

Survodutide vs mazdutide

Survodutide and mazdutide belong to the same class: both are once-weekly peptides that activate the glucagon receptor and the GLP-1 receptor 1,2. Survodutide is investigational, with phase 3 results published in 2026, while mazdutide was approved in China in 2025 1,3. Neither had a Drugs@FDA application record when queried on 24 October 2026 4,5. No trial comparing them directly was identified 6,7.

Unbranded reference vial illustrating Survodutide; not an actual product
Survodutide
Investigational
Unbranded reference vial illustrating Mazdutide; not an actual product
Mazdutide
Approved outside the US

Side by side

FieldSurvodutideMazdutide
ClassDual glucagon receptor and GLP-1 receptor agonist (investigational) 1Dual GLP-1 receptor and glucagon receptor agonist 2,3
Origin and structureAcylated peptide carrying a C18 fatty acid as a half-life-extending element 8Synthetic oxyntomodulin analogue with a fatty-acyl side chain to extend half-life 9
Proposed mechanismIn mice, reduced food intake and increased energy expenditure; engagement of both receptors shown with knockout and reporter mice 8Binds GLP-1 and glucagon receptors in vitro; in mice, body-weight reduction persisted in knockout animals lacking either receptor 9
Half-lifeNot located in the sources reviewed150.9 to 403.5 hours in a phase 1b study in Chinese adults with overweight or obesity 9
Highest human trial phasePhase 3 (SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-MASLD published; 12 phase 3 registry entries) 1,6,10,11Phase 3 published; phase 4 studies registered in China 2,7,12
FDA statusNot approved; no Drugs@FDA application record as of 24 October 2026 4Not FDA-approved (no Drugs@FDA record as of 24 October 2026) 5; approved in China in 2025 3
Published human outcomesSYNCHRONIZE-1: -12.2% and -13.0% vs -5.4% with placebo at 76 weeks 1; SYNCHRONIZE-MASLD: 84.2% vs 24.3% had at least a 30% fall in liver fat (efficacy estimand) 11GLORY-1: -11.00% and -14.01% vs +0.30% at 48 weeks 2; GLORY-2: -16.65% vs -1.50% at 60 weeks 12
Safety signalsGastrointestinal events in 80.9% and 89.7% of survodutide groups vs 47.9% with placebo in SYNCHRONIZE-1 1; 37% of treated men withdrew from dose escalation for adverse events in a Japanese phase 1 study 13Mainly gastrointestinal; vomiting 53.1% vs 1.3% with placebo in GLORY-2 12; 20% discontinued for adverse events at the highest dose in the US phase 2 trial 14
WADA statusNot named on the 2026 Prohibited List; class S0 covers drugs under clinical development with no current approval by any governmental health authority 15Not named on the 2026 Prohibited List; S0 applies only to substances with no current approval anywhere, and mazdutide is approved in China 3,15
Who funded the evidenceBoehringer Ingelheim 1,10,16Innovent Biologics (Chinese trials) and Eli Lilly (US phase 2) 2,14

Survodutide: what the data says

Survodutide's phase 3 programme covers obesity with and without type 2 diabetes and liver disease, funded by Boehringer Ingelheim 1,10,11.

  • In SYNCHRONIZE-1 (725 adults without diabetes; human data), mean body-weight change at 76 weeks was -12.2% and -13.0% in the two dose groups vs -5.4% with placebo 1.
  • In SYNCHRONIZE-2 (752 adults with type 2 diabetes; human data), the change was -8.2% and -9.8% vs -3.9%, and HbA1c fell by 0.8 to 0.9 percentage points vs 0.2 10.
  • In a phase 2 trial in biopsy-confirmed MASH (293 participants; human data), improvement in MASH without worsening of fibrosis occurred in 43% to 62% of survodutide groups vs 14% with placebo 17.

Mazdutide: what the data says

Mazdutide's phase 3 trials were conducted in China and funded by Innovent Biologics; a US phase 2 trial was funded by Eli Lilly 2,14.

  • In GLORY-1 (610 adults; human data), mean body-weight change at 48 weeks was -11.00% and -14.01% vs +0.30% with placebo 2.
  • In GLORY-2 (461 adults with obesity; human data), the change at 60 weeks was -16.65% vs -1.50% 12.
  • In type 2 diabetes (human data), mazdutide lowered HbA1c compared with placebo and with dulaglutide 18,19.

Key research differences

  • Regulatory status: mazdutide is approved in China, whereas survodutide has no approval identified; neither had a Drugs@FDA record on 24 October 2026 3,4,5.
  • Liver-disease evidence: survodutide has a published phase 3 trial in MASLD and a phase 2 biopsy trial in MASH, whereas the mazdutide sources reviewed report a MASH trial only as registered 7,11,17.
  • Trial geography: mazdutide's published phase 3 trials enrolled Chinese adults, whereas survodutide's SYNCHRONIZE-2 was multinational 2,10,12.
  • Pharmacokinetic reporting: a phase 1b half-life range is published for mazdutide, while no numeric human half-life for survodutide was located 9.
  • Placebo-group change: placebo groups in SYNCHRONIZE-1 lost 5.4% of body weight vs a 0.30% gain in GLORY-1, showing how differently these trials performed 1,2.

Where the evidence is limited

No head-to-head trial was identified 6,7. The trials differ in length (76 weeks vs 48 to 60 weeks), population, lifestyle co-interventions and placebo response, so the figures cannot be ranked 1,2,12. Each programme was funded by its developer 1,2.

Frequently asked questions

Are survodutide and mazdutide the same type of drug?
Yes, in terms of receptor targets: both are dual glucagon and GLP-1 receptor agonists given once weekly 1,2. They are different molecules from different developers 8,9.
Does survodutide lead to more body-weight change than mazdutide?
That cannot be determined. No trial has compared them, and their phase 3 trials differ in duration, population and placebo response 1,2,6.
Is either approved?
Mazdutide was approved in China in 2025 3. Neither had a Drugs@FDA application record on 24 October 2026, and survodutide is described as investigational in its 2026 phase 3 reports 1,4,5.

References

  1. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1) N Engl J Med. 2026
  2. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1) N Engl J Med. 2025
  3. Mazdutide: First Approval Drugs. 2025
  4. Drugs@FDA application data queried through openFDA for survodutide (no matching application record returned on 24 October 2026) openFDA / Drugs@FDA. 2026
  5. Drugs@FDA application data queried through openFDA for mazdutide (no matching application record returned on 24 October 2026) openFDA / Drugs@FDA. 2026
  6. ClinicalTrials.gov registry search for survodutide as intervention (29 records, 12 phase 3; retrieved 24 October 2026) ClinicalTrials.gov. 2026
  7. ClinicalTrials.gov registry search for mazdutide as intervention (43 records; phase 3 and phase 4 entries listed; retrieved 24 October 2026) ClinicalTrials.gov. 2026
  8. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy Mol Metab. 2022
  9. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study (full text) EClinicalMedicine. 2021
  10. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (SYNCHRONIZE-2) N Engl J Med. 2026
  11. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Nat Med. 2026
  12. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial JAMA. 2026
  13. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity Diabetes Obes Metab. 2023
  14. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial Lancet Diabetes Endocrinol. 2026
  15. The 2026 Prohibited List - World Anti-Doping Code, as published in the Netherlands Treaty Series (Tractatenblad 2026, 25; Council of Europe Anti-Doping Convention appendix, in force 1 January 2026) Tractatenblad (Official Publications of the Kingdom of the Netherlands). 2026
  16. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial Lancet Diabetes Endocrinol. 2024
  17. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis N Engl J Med. 2024
  18. Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature. 2026
  19. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes Nature. 2026

For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page compares published research and is not medical advice or a recommendation.